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ABSTRACT BODY: 
Abstract Body: Introduction. Obesity is a chronic disease characterized by low-grade systemic inflammation and by
alteration in gastrointestinal motility. Recently, the beneficial effects of flavonoids in the prevention of some
comorbidities associated with obesity have been reported. However, their putative effects in counteracting the enteric
functional disorders related to obesity have not been investigated. This study examines the effect of dietary
supplementation with luteolin, apigenin and naringenin on colonic motor and inflammatory abnormalities in a mouse
model of diet-induced obesity.
Methods. C57BL/6 mice (n=5/group) were fed with standard diet (SD, 18% calories from fat) or a high-fat diet (HFD,
60% calories from fat) for 8 weeks. Subgroups of mice on SD or HFD were treated for 8 weeks with luteolin (10
mg/Kg/die), apigenin (10 mg/Kg/die) and naringenin (10 mg/Kg/die). At the end of the treatments, body and
epididymal fat weight, as well as blood cholesterol, triglycerides and glucose levels were evaluated. Malondialdehyde
(MDA), IL-1β and IL-6 levels in colonic tissue were also examined. Colonic longitudinal muscle strips (LMS) were set
up in organ baths with Krebs solution and connected to isometric transducers to record contractions elicited by
electrical stimulation (ES, 10 Hz, 0.5 msec, 30 mA). Nω-nitro-L-arginine methylester, alone or in combination with
guanethidine, atropine, NK2 and NK3 receptor antagonists were used to record nitrergic and NK1 receptor-mediated
tachykininergic motor responses.
Results. When compared with SD mice, HFD animals displayed an increase in body and epididymal fat weight with
alterations of blood metabolic indexes (Table 1). Colonic tissues from HFD mice showed also an increase in MDA, IL-
1β and IL-6 levels versus SD mice (Table 1). Colonic LMS obtained from obese mice displayed an enhancement of
electrically evoked nitrergic and tachykininergic responses (+48% and +126% vs SD mice, respectively). Dietary
supplementation with luteolin, apigenin, and naringenin counteracted the increase of body and epididymal fat weight,
as well as the alterations of metabolic indexes in HFD-fed mice (Table 1). In addition, flavonoids administration
reduced MDA, IL-1β, IL-6 tissue levels in obese animals (Table 1). Luteolin, apigenin and naringenin treatment
normalized the enhancement of colonic nitrergic and tachykininergic contractions. Of note, treatment with flavonoids
did not induce significant changes in metabolic, inflammatory and functional parameters in SD-fed animals, in
comparison with untreated mice.
Conclusion. Diet-supplementation with luteolin, apigenin and naringenin prevented metabolic alterations associated
with obesity. Moreover, flavonoids administration resulted in a reduction of intestinal inflammation and in counteract
the colonic contractile dysfunctions associated with obesity.
TABLE: 
Table of the results
. SD HFD HFD+luteolin HFD+apigeni
n
HFD+naringe
nin
Body and
epididymal
fat weight
.
Body weight
gain (%)
36±2 74±2.6a 46±2* 20±1.8# 28±3.3*
Epididymal
fat weight (g)
0.3±0.02 1.8±0.1c 0.9±0.08* 0.5±0.03$ 0.6±0.09$
Metabolic
indexes
.
Cholesterol
(mg/dL)
145±5.4 182±7.7a 146±7.5* 142±5.3* 134±3.2#
Triglycerides
(mg/dL)
118±2.4 149.5±0.03a 143±8.5 109±6.8* 112±2.8*
Glucose
(mg/dL)
128±7 166±4.8a 133±6* 120±7.3* 116±8.1*
Inflammatory
 parameters
.
MDA
(nmol/mg
tissue)
21 ± 2 59 ± 3.1c 33.5 ± 3.9* 29 ± 2.3* 36.4 ± 4 #
IL-1β (pg/mg
tissue)
3.6±0.04 7.6±0.4c 2.1±0.6# 3.3±0.2# 1.8±0.1#
IL-6 (pg/mg
tissue)
0.08±0.01 0.38 ± 0.05a 0.06±0.01* 0.1±0.07* 0.12±0.02*
aP < 0.05,  cP < 0.001 versus SD
*P < 0.05, $P < 0.01, #P < 0.001 versus HFD
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